Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

27 août 2020 mis à jour par: Sunstar Americas

A Randomized, Double-Blind, Controlled, Multicenter Dose Verification Clinical Trial to Evaluate the Safety and Effectiveness of GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

This will be a prospective, randomized, double-blinded, controlled, multi-center, dose-verification clinical study in subjects who require surgical intervention to treat a qualifying periodontal defect.

Subjects 25 years and older with advanced periodontal disease in at least one site requiring surgical treatment to correct a bone defect.

Type d'étude

Interventionnel

Inscription (Réel)

88

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Alabama
      • Birmingham, Alabama, États-Unis, 35294
        • University of Alabama at Birmingham
    • California
      • Fullerton, California, États-Unis, 92835
        • Regenerative Solutions
    • Colorado
      • Aurora, Colorado, États-Unis, 80012
        • Drs. McClain and Schallhorn
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48106
        • University of Michigan
    • Texas
      • Houston, Texas, États-Unis, 77063
        • Perio Health Professionals
      • San Antonio, Texas, États-Unis, 78229
        • University of Texas Health Science Center at San Antonio

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

25 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female, age of 25 and older
  • Must have read, understood, and signed a consent form
  • Must be able and willing to follow study procedures and instructions
  • Must have undergone thorough scaling and root planing of the target tooth and be expected to demonstrate good plaque control after instruction in oral hygiene

  • The target tooth must exhibit the following:

    • A pocket depth of 7 mm or greater
    • After surgical debridement, 4 mm or greater intrabony defect with at least 1 bony wall
    • Sufficient keratinized tissue to allow complete tissue coverage of the defect
    • Radiographic base of defect at least 3 mm coronal to the apex of the tooth

Exclusion Criteria:

  • Failure to maintain adequate oral hygiene during the screening phase
  • Women of child-bearing potential
  • A history within the last 6 months of HIV, Type IV heart disease, or end-stage renal disease
  • A history of oral cancer or any other cancer (exception: subjects with a history of skin cancers such as squamous and basal carcinoma with end of treatment at least 6 months ago and/or prostate cancer with end of treatment at least 5 years ago may be enrolled)
  • A history within 12 months of previous open flap periodontal surgery on the study tooth.
  • A diagnosis of pre-malignant oral lesion(s)
  • A traumatic occlusion of the target tooth
  • Target "study" tooth exhibiting Grade III mobility
  • Maxillary molars or maxillary first premolar with a prominent mesial concavity
  • Study tooth exhibiting a Class II or greater furcation defect
  • Clinical or radiographic signs of untreated acute or chronic periapical infection at the surgical site, apical pathology, root fracture, severe root irregularities, cemental pearls, cervical enamel projections not easily removed by odontoplasty, untreated carious lesions at the cemento-enamel junction (CEJ) or on the root surface, or restorations with open or otherwise defective margins at or below the CEJ
  • A history within the last 6 months of the daily use of any tobacco products besides cigarettes (smokeless chewing tobacco, pipe or cigar smoking), or of smoking more than 10 cigarettes per day
  • Subjects participating in other clinical trials within 30 days of enrollment
  • Subjects having uncontrolled endocrine-induced diseases (e.g. uncontrolled diabetes mellitus and hyperparathyroidism)
  • Subjects undergoing current therapy with systemic steroids or other drugs that significantly alter bone metabolism
  • Subjects with Localized Juvenile Periodontitis (LJP) sites in the oral cavity

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: beta-tricalcium phosphate alone
Dispositif: beta-tricalcium phosphate alone
Expérimental: GFeBGS 0.1%
GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
Dispositif: GFeBGS 0.1%
Expérimental: GFeBGS 0.3%
GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
Dispositif: GFeBGS 0.3%
Expérimental: GFeGBS 0.4%
GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
Dispositif: GFeBGS 0.4%

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants That Met the Success Criteria of Radiographic and Clinical Measurements
Délai: 6 months post-surgery
The primary effectiveness endpoint is a composite endpoint that considers radiographic and clinical measurements at six months post-implantation: the amount of linear bone growth (LBG), which is assessed with the use of radiographs, and the regain from baseline of clinical attachment level (∆CAL), which is assessed clinically. Linear bone growth (LBG) in a vertical and horizontal direction is determined radiographically at six months post-implantation. The clinical attachment level (CAL) is the distance from the cemento-enamel junction (CEJ) (or other fixed reference point) generally along the long axis of the tooth to the deepest extent of the periodontal pocket. The success criteria are ΔCAL ≥1.5 mm and LBG ≥1 mm at 6 months after the treatment. Both the ∆CAL and LBG must meet the success criteria for a subject to be considered a success.
6 months post-surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Clinical Attachment Level at 3 Months
Délai: Baseline and 3 months post-surgery
The clinical attachment level is the distance from the cemento-enamel junction (or other fixed reference point) generally along the long axis of the tooth to the deepest extent of the periodontal pocket. Change = (3 months measurement - Baseline measurement)
Baseline and 3 months post-surgery
Change in Clinical Attachment Level at 6 Months
Délai: Baseline and 6 months post-surgery
The clinical attachment level is the distance from the cemento-enamel junction (or other fixed reference point) generally along the long axis of the tooth to the deepest extent of the periodontal pocket. Change = (6 months measurement - Baseline measurement)
Baseline and 6 months post-surgery
Linear Bone Growth at 6 Months
Délai: Baseline and 6 months post-surgery
Linear measurement of bone height in millimeters along mesial and/or distal root surfaces of the defect site is captured radiographically at baseline and 6 months. Linear Bone Growth = (Baseline measurement - 6 months measurement)
Baseline and 6 months post-surgery
Percent Bone Fill at 6 Months
Délai: Baseline and 6 months post-surgery
Linear measurement of bone height in millimeters along mesial and/or distal root surfaces of the defect site is captured radiographically at baseline and 6 months. Percent Bone Fill is calculated by dividing Linear Bone Growth at 6 months by bone height at baseline.
Baseline and 6 months post-surgery
Pocket Depth Change at 3 Months
Délai: Baseline and 3 months post-surgery
Length from free gingival margin to the base of the pocket in millimeter is measured with North Carolina 15 mm periodontal probes. Pocket Depth Change = (3 months measurement - Baseline measurement)
Baseline and 3 months post-surgery
Pocket Depth Change at 6 Months
Délai: Baseline and 6 months post-surgery
Length from free gingival margin to the base of the pocket in millimeter is measured with North Carolina 15 mm periodontal probes. Pocket Depth Change = (6 months measurement - Baseline measurement)
Baseline and 6 months post-surgery
Change in Gingival Recession at 3 Months
Délai: Baseline and 3 months post-surgery
Length from the free gingival margin to the CEJ is measured in millimeter with North Carolina 15 mm periodontal probes. Gingival Recession = (3 months measurement - Baseline measurement)
Baseline and 3 months post-surgery
Change in Gingival Recession at 6 Months
Délai: Baseline and 6 months post-surgery
Length from the free gingival margin to the CEJ is measured in millimeter with North Carolina 15 mm periodontal probes. Gingival Recession = (6 months measurement - Baseline measurement)
Baseline and 6 months post-surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Sunstar Americas

Les enquêteurs

  • Chercheur principal: David L. Cochran, DDS, PhD, University of Texas Health Sciences Center at San Antonio

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 octobre 2012

Achèvement primaire (Réel)

1 août 2014

Achèvement de l'étude (Réel)

1 août 2014

Dates d'inscription aux études

Première soumission

1 novembre 2012

Première soumission répondant aux critères de contrôle qualité

16 novembre 2012

Première publication (Estimation)

20 novembre 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 septembre 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 août 2020

Dernière vérification

1 août 2020

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • CLP-2011-10-31-1

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner